Barclays PLC Buys 137,936 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Barclays PLC lifted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 149.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,177 shares of the company’s stock after buying an additional 137,936 shares during the quarter. Barclays PLC’s holdings in Adaptive Biotechnologies were worth $1,180,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. JTC Employer Solutions Trustee Ltd bought a new position in Adaptive Biotechnologies in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Adaptive Biotechnologies in the third quarter worth $34,000. MQS Management LLC bought a new stake in Adaptive Biotechnologies during the second quarter valued at $36,000. Rothschild Investment LLC purchased a new position in Adaptive Biotechnologies during the second quarter worth about $36,000. Finally, Townsquare Capital LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter worth about $56,000. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Trading Down 2.3 %

Shares of NASDAQ:ADPT opened at $6.29 on Monday. The company has a 50-day moving average price of $5.65 and a 200-day moving average price of $4.78. The company has a market cap of $928.27 million, a price-to-earnings ratio of -4.69 and a beta of 1.49. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $7.07.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ADPT. Piper Sandler raised their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.